For medtech and pharma companies, it presents an opportunity to close the gap between the health data that’s needed to develop these patient-centric solutions and the health data available to them. Beyond that, the EHDS will bring players from the life sciences, medical devices, and healthcare provider sector closer together, enabling new collaborative ecosystems.
We’re convinced that regulated Digital Health Platforms (DHPs) will play a major role in enabling medtech and pharma companies to realise this opportunity. Organisations which embrace those developments first and implement DHPs, will have a major advantage when the EHDS comes into effect.
That’s why we brought together our wider Zühlke community to discuss the role (and potential shortcomings) of DHPs in the future of healthcare, and how they enable the advent of a connected health ecosystem, thereby integrating various digital health solutions together for a seamless patient journey.
In our discussion, we outlined the key strategic technology choices healthcare players must make, and the success factors which drive them.
Together, we explored questions such as:
- How does the European Health strategy and the EHDS impact current health data (platform) strategies?
- What models can medtech and pharma companies use when partnering directly with cloud providers or DHP providers?
- What are the key considerations for medtech and pharma companies or healthcare institutions when choosing a platform environment?
If you would like to know more about that topic we recommend to read our whitepaper and blogposts: